Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UCB and its US-based partner Immunomedics have announced Epratuzumab phase IIb data demonstrating the sensitivity of BICLA, in systemic lupus erythematosus (SLE).
Subscribe to our email newsletter
Epratuzumab is a humanised monoclonal antibody targeting CD22 and modulating B-cell activity.
The data supported the BILAG-based Combined Lupus Assessment (BICLA) as a clinically meaningful composite measure of systemic lupus erythematosus (SLE) disease activity.
The British Isles Lupus Assessment Group (BILAG) index is a comprehensive, validated tool for assessing lupus disease activity.
In the EMBLEM study, all epratuzumab doses, ranging from 200mg to 3600mg dose administered during one 12-week treatment cycle had numerically superior BICLA response rates compared to placebo at week 12.